Implementing Curcumin in Translational Oncology Research.

作者: Koraljka Gall Trošelj , Ivana Samaržija , Marko Tomljanović , Renata Novak Kujundžić , Nikola Đaković

DOI: 10.3390/MOLECULES25225240

关键词:

摘要: Most data published on curcumin and curcumin-based formulations are very promising. In cancer research, the majority of has been obtained in vitro. Less frequently, researchers used experimental animals. The results several clinical studies conclusive, these have established a good foundation for further research focusing implementing oncology. However, issues regarding timely reporting lack disclosure exact should not be neglected. This article is snapshot current status publicly available trials detailed presentation so far with some formulations. Phenomena related to observed effects shown presented, its modifying effect gut microbiota metabolic reprogramming discussed. Based data, there strong indication that metabolites present molecules do necessarily need abundant order act locally benefit systemically. Future designed way will take fact into consideration.

参考文章(174)
Raymond B. Weiss, Michaele C. Christian, New cisplatin analogues in development. A review. Drugs. ,vol. 46, pp. 360- 377 ,(1993) , 10.2165/00003495-199346030-00003
G Appendino, G Ciammaichella, R Luzzi, S Togni, G Belcaro, A Ledda, M Dugall, M Scoccianti, Meriva®, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: a pilot, product evaluation registry study. Panminerva Medica. ,vol. 54, pp. 17- 22 ,(2012)
Wenjing Zhang, Xinpeng Shi, Ying Peng, Meiyan Wu, Pei Zhang, Ruyi Xie, Yao Wu, Qingqing Yan, Side Liu, Jide Wang, HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer. PLOS ONE. ,vol. 10, ,(2015) , 10.1371/JOURNAL.PONE.0129603
Dinesh Chandra, Arthee Jahangir, Francois Cornelis, Klara Rombauts, Lydie Meheus, Cheryl L Jorcyk, Claudia Gravekamp, Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer. OncoImmunology. ,vol. 5, ,(2016) , 10.1080/2162402X.2015.1049802
Gianni Belcaro, Morio Hosoi, Luciano Pellegrini, Giovanni Appendino, Edmondo Ippolito, Andrea Ricci, Andrea Ledda, Mark Dugall, Maria Rosaria Cesarone, Claudia Maione, Giovanna Ciammaichella, Domenico Genovesi, Stefano Togni, A Controlled Study of a Lecithinized Delivery System of Curcumin (Meriva®) to Alleviate the Adverse Effects of Cancer Treatment Phytotherapy Research. ,vol. 28, pp. 444- 450 ,(2014) , 10.1002/PTR.5014
Mark I. James, Chinenye Iwuji, Glen Irving, Ankur Karmokar, Jennifer A. Higgins, Nicola Griffin-Teal, Anne Thomas, Peter Greaves, Hong Cai, Samita R. Patel, Bruno Morgan, Ashley Dennison, Matthew Metcalfe, Giuseppe Garcea, David M. Lloyd, David P. Berry, William P. Steward, Lynne M. Howells, Karen Brown, Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Letters. ,vol. 364, pp. 135- 141 ,(2015) , 10.1016/J.CANLET.2015.05.005
Christopher D Lao, Mack T Ruffin, Daniel Normolle, Dennis D Heath, Sandra I Murray, Joanne M Bailey, Martha E Boggs, James Crowell, Cheryl L Rock, Dean E Brenner, Dose escalation of a curcuminoid formulation. BMC Complementary and Alternative Medicine. ,vol. 6, pp. 10- 10 ,(2006) , 10.1186/1472-6882-6-10
Alan Yueh-Luen Lee, Chi-Chen Fan, Yen-An Chen, Chieh-Wen Cheng, Ya-Ju Sung, Chih-Ping Hsu, Ting-Yu Kao, Curcumin Inhibits Invasiveness and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Through Reducing Matrix Metalloproteinase 2, 9 and Modulating p53-E-Cadherin Pathway Integrative Cancer Therapies. ,vol. 14, pp. 484- 490 ,(2015) , 10.1177/1534735415588930
VinayK Hazarey, AditeeR Sakrikar, SindhuM Ganvir, Efficacy of curcumin in the treatment for oral submucous fibrosis - A randomized clinical trial. Journal of Oral and Maxillofacial Pathology. ,vol. 19, pp. 145- 152 ,(2015) , 10.4103/0973-029X.164524
Yoshikane Yamauchi, Yotaro Izumi, Jun Yamamoto, Hiroaki Nomori, Coadministration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells. Phytotherapy Research. ,vol. 28, pp. 728- 735 ,(2014) , 10.1002/PTR.5056